Temporary discontinuation In the Stark case series, both patients who discontinued semaglutide experienced complete resolution of allodynia symptoms
These tend to be most significant in the early weeks and during dose escalation, and they interact badly with several common travel situations
Semaglutide treatment in conjunction with SGLT-2 inhibitor led to significant reduction in HbA1c and body weight
In SCALE TEENS, the group receiving liragludtide had an estimated treatment difference in BMI of 5.01% compared with placebo, whereas the estimated treatment difference in STEP TEENS between the semaglutide and placebo groups was 16.7%
The truth is that, unfortunately, weight loss pills almost never work
Mounjaro posed the most significant risk, with users facing more than a 50% higher likelihood of serious GI complications compared to SGLT-2 inhibitors like Januvia and Farxiga